Retrieve available abstracts of 214 articles: HTML format
Single Articles
May 2025
PLOUSSARD G, Coloby P, Chevallier T, Occean BV, et al Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical
Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.
Eur Urol. 2025;87:526-533. PubMedAbstract available
April 2025
GOMEZ RIVAS J, Moreno Sierra J Re: Darolutamide in Combination with Androgen-deprivation Therapy in Patients
with Metastatic Hormone-sensitive Prostate Cancer from the Phase III ARANOTE
Trial.
Eur Urol. 2025 Apr 23:S0302-2838(25)00208-8. doi: 10.1016/j.eururo.2025. PubMed
GOMEZ RIVAS J, Moreno Sierra J Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic
Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre,
Randomised, Phase 2 Trial.
Eur Urol. 2025 Apr 22:S0302-2838(25)00207-6. doi: 10.1016/j.eururo.2025. PubMed
VICKERS A, Touijer K Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al.
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I:
Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol
2024;86:148-63.
Eur Urol. 2025 Apr 12:S0302-2838(25)00200-3. doi: 10.1016/j.eururo.2025. PubMed
ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al Corrigendum to "Association of Declining Prostate-specific Antigen Levels with
Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate
Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86
(2024) 552-562
Eur Urol. 2025 Apr 8:S0302-2838(25)00179-4. doi: 10.1016/j.eururo.2025. PubMed
CHEN S, Xu H, Chen X, Shen Q, et al First-in-human Study of a Dual-modality Prostate-specific Membrane
Antigen-targeted Probe for Preoperative Positron Emission Tomography/Computed
Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer.
Eur Urol. 2025 Apr 8:S0302-2838(25)00182-4. doi: 10.1016/j.eururo.2025. PubMedAbstract available
ROBERTS MJ, Gandaglia G, Oprea-Lager DE, Stranne J, et al Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications.
Eur Urol. 2025 Apr 7:S0302-2838(25)00154-X. doi: 10.1016/j.eururo.2025. PubMedAbstract available
March 2025
MAZZONE E, Cannoletta D, Quarta L, Chen DC, et al A Comprehensive Systematic Review and Meta-analysis of the Role of
Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate
Cancer Diagnosis and Primary Staging before Definitive Treatment.
Eur Urol. 2025 Mar 27:S0302-2838(25)00155-1. doi: 10.1016/j.eururo.2025. PubMedAbstract available
MONTORSI F, Gandaglia G, Barletta F, Briganti A, et al Re: Andreas Josefsson, Marianne Mansson, Kimia Kohestani, et al. Performance of
4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate
Cancer Screening Trial. Eur Urol 2024;86:223-9.
Eur Urol. 2025 Mar 26:S0302-2838(25)00124-1. doi: 10.1016/j.eururo.2025. PubMed
SHAH RB, Paner GP, Cheng L, De Marzo AM, et al Genitourinary Pathology Society and International Society of Urological Pathology
White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary
Approach.
Eur Urol. 2025 Mar 17:S0302-2838(25)00150-2. doi: 10.1016/j.eururo.2025. PubMedAbstract available
HAGE CHEHADE C, Ozay ZI, Ostrowski M, Mercinelli C, et al T-cell Engagers in Prostate Cancer.
Eur Urol. 2025 Mar 11:S0302-2838(25)00070-3. doi: 10.1016/j.eururo.2025. PubMedAbstract available
DEVOS G, Giesen A, Joniau S When Less Is More: The Challenges of Defining Residual Disease Following
Neoadjuvant Hormonal Therapy in Prostate Cancer.
Eur Urol. 2025 Mar 10:S0302-2838(25)00146-0. doi: 10.1016/j.eururo.2025. PubMed
TAHA T, Koster KL, de Bono JS T-Cell Engagers in Prostate Cancer: Promise, Challenges, and the Road Ahead.
Eur Urol. 2025 Mar 5:S0302-2838(25)00147-2. doi: 10.1016/j.eururo.2025. PubMed
GILLESSEN S, Tombal B, Turco F, Choudhury A, et al Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC
1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus
Enzalutamide Alone: A Safety Analysis.
Eur Urol. 2025;87:285-288. PubMedAbstract available
February 2025
FREEDLAND SJ, Mulhall JP, Gleave M, Giorgi U, et al Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically
Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in
the EMBARK Study.
Eur Urol. 2025 Feb 26:S0302-2838(25)00094-6. doi: 10.1016/j.eururo.2025. PubMedAbstract available
AZAD AA, Kostos L, Agarwal N, Attard G, et al Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive
Prostate Cancer.
Eur Urol. 2025 Feb 12:S0302-2838(25)00023-5. doi: 10.1016/j.eururo.2025. PubMedAbstract available
RAVI P, Kwak L, Acosta AM, Rastogi S, et al Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After
Intensified Neoadjuvant Therapy in High-risk Prostate Cancer.
Eur Urol. 2025 Feb 6:S0302-2838(25)00027-2. doi: 10.1016/j.eururo.2025. PubMedAbstract available
CASTRO E, Lorente D, Olmos D PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the
Chaff.
Eur Urol. 2025 Feb 3:S0302-2838(25)00024-7. doi: 10.1016/j.eururo.2025. PubMed
MORGAN TM, Daignault-Newton S, Spratt DE, Dunn RL, et al Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following
Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover
Trial.
Eur Urol. 2025;87:228-237. PubMedAbstract available
January 2025
BERNARDINO RM, van der Kwast T, Fleshner NE Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and
Emerging Perspectives.
Eur Urol. 2025 Jan 30:S0302-2838(25)00025-9. doi: 10.1016/j.eururo.2025. PubMedAbstract available
NAQVI SAA, Riaz IB, Bibi A, Khan MA, et al Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic
Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and
Meta-analysis.
Eur Urol. 2025 Jan 22:S0302-2838(24)02760-X. doi: 10.1016/j.eururo.2024. PubMedAbstract available
MURTHY V, Marvaso G, Jereczek-Fossa BA, Thoma SA, et al The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron
Emission Tomography and Radiotherapy in Prostate Cancer Care.
Eur Urol. 2025 Jan 20:S0302-2838(25)00008-9. doi: 10.1016/j.eururo.2025. PubMedAbstract available
LONGONI M, Briganti A, Gandaglia G, Montorsi F, et al Re: Metastatic Hormone-sensitive Prostate Cancer and Combination Treatment
Outcomes: A Review.
Eur Urol. 2025 Jan 10:S0302-2838(25)00001-6. doi: 10.1016/j.eururo.2025. PubMed
LEENEN RCA, Roobol MJ, Beyer K Reply to Jonas Hugosson. Population-based Screening for Prostate Cancer: Is It
Time? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.003.
Eur Urol. 2025 Jan 4:S0302-2838(24)02767-2. doi: 10.1016/j.eururo.2024. PubMed
EL-TAJI O, Clarke NW Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for
Precision in Treatment Strategies.
Eur Urol. 2025;87:27-28. PubMed
ONG WL, Romero T, Roy S, Nikitas J, et al Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy
(TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis
of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.
Eur Urol. 2025;87:49-57. PubMedAbstract available
December 2024
STRANNE J, Henry A, Oprea-Lager DE Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed
Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A
Continuing Conundrum.
Eur Urol. 2024 Dec 18:S0302-2838(24)02745-3. doi: 10.1016/j.eururo.2024. PubMedAbstract available
TISSEVERASINGHE S, Tolba M, Saad F, Fizazi K, et al Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer:
Does Local Radiotherapy Play a Role in High-volume Disease?
Eur Urol. 2024 Dec 17:S0302-2838(24)02748-9. doi: 10.1016/j.eururo.2024. PubMedAbstract available
DIAS AB, Moore CM, Renard-Penna R, Giganti F, et al Biparametric Versus Multiparametric Magnetic Resonance Imaging in Prostate
Cancer: A Choice or a Fine Balance?
Eur Urol. 2024 Dec 16:S0302-2838(24)02740-4. doi: 10.1016/j.eururo.2024. PubMed
DAVIS JW Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy-A New
Standard for Guidelines on Prostate Cancer Detection?
Eur Urol. 2024 Dec 11:S0302-2838(24)02717-9. doi: 10.1016/j.eururo.2024. PubMed
SCHAFER EJ, Laversanne M, Sung H, Soerjomataram I, et al Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An
Update.
Eur Urol. 2024 Dec 5:S0302-2838(24)02707-6. doi: 10.1016/j.eururo.2024. PubMedAbstract available
November 2024
MADEC FX, Mesnard B, Dariane C Re: Prevalence and Factors Associated with Prostate Cancer Among Transgender
Women.
Eur Urol. 2024 Nov 21:S0302-2838(24)02704-0. doi: 10.1016/j.eururo.2024. PubMed
COOPERBERG MR Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI
(PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
Eur Urol. 2024 Nov 21:S0302-2838(24)02700-3. doi: 10.1016/j.eururo.2024. PubMed
HUGOSSON J Population-based Screening for Prostate Cancer: Is it Time?
Eur Urol. 2024 Nov 20:S0302-2838(24)02696-4. doi: 10.1016/j.eururo.2024. PubMed
DAHM P, Wilt TJ Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
Eur Urol. 2024 Nov 15:S0302-2838(24)02687-3. doi: 10.1016/j.eururo.2024. PubMed
KISHAN AU, Lamb JM, Wilhalme H, Casado M, et al Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic
Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized
Clinical Trial.
Eur Urol. 2024 Nov 12:S0302-2838(24)02688-5. doi: 10.1016/j.eururo.2024. PubMedAbstract available
GHADJAR P, Zips D Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for
Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen
Deprivation Therapy in the RADICALS-HD Randomised Trial.
Eur Urol. 2024 Nov 12:S0302-2838(24)02691-5. doi: 10.1016/j.eururo.2024. PubMed
ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission
Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy
Management: Results from a Prospective Multicenter Randomized Phase 3 Trial
(PSMA-SRT NCT03582774)" [
Eur Urol. 2024 Nov 8:S0302-2838(24)02684-8. doi: 10.1016/j.eururo.2024. PubMed
PARKER CC, Clarke NW, Cook AD, Petersen PM, et al Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy
with Postoperative Radiotherapy After Radical Prostatectomy: Results from the
Three-way Comparison of RADICALS-HD (NCT00541047).
Eur Urol. 2024;86:422-430. PubMedAbstract available
LANE BR, Dess RT, Borza T More Than Words: Defining Adjuvant, Consolidative, and Salvage Treatment after
Radical Prostatectomy.
Eur Urol. 2024;86:385-387. PubMedAbstract available
October 2024
OH WK, Agarwal N, Bryce A, Barata P, et al What's in a Name? Why Words Matter in Advanced Prostate Cancer.
Eur Urol. 2024 Oct 28:S0302-2838(24)02680-0. doi: 10.1016/j.eururo.2024. PubMedAbstract available
TOUIJER KA, Vertosick EA, Sjoberg DD, Liso N, et al Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized
Clinical Trial of Limited Versus Extended Dissection.
Eur Urol. 2024 Oct 28:S0302-2838(24)02647-2. doi: 10.1016/j.eururo.2024. PubMedAbstract available
TWILT JJ, Saha A, Bosma JS, van Ginneken B, et al Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for
Diagnosing Clinically Significant Prostate Cancer: An International, Paired,
Noninferiority, Confirmatory Observer Study.
Eur Urol. 2024 Oct 21:S0302-2838(24)02640-X. doi: 10.1016/j.eururo.2024. PubMedAbstract available
VANDERWEELE DJ, Hussain M Management Decisions for Metastatic Castration-resistant Prostate Cancer in 2024.
Eur Urol. 2024 Oct 19:S0302-2838(24)02646-0. doi: 10.1016/j.eururo.2024. PubMed
EVANGELISTA L, Cecchi L, Zucali PA Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen-based
Radioligand Therapy at the Forefront.
Eur Urol. 2024 Oct 19:S0302-2838(24)02645-9. doi: 10.1016/j.eururo.2024. PubMed
FENDLER WP, Grunwald V, Herrmann K, Hadaschik BA, et al Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized
Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall
Survival in Prostate Cancer.
Eur Urol. 2024 Oct 19:S0302-2838(24)02648-4. doi: 10.1016/j.eururo.2024. PubMedAbstract available
GILLESSEN S, Turco F, Davis ID, Efstathiou JA, et al Management of Patients with Advanced Prostate Cancer. Report from the 2024
Advanced Prostate Cancer Consensus Conference (APCCC).
Eur Urol. 2024 Oct 10:S0302-2838(24)02610-1. doi: 10.1016/j.eururo.2024. PubMedAbstract available
BAKHT MK, Beltran H Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naive
Prostate Cancer.
Eur Urol. 2024 Oct 10:S0302-2838(24)02637-X. doi: 10.1016/j.eururo.2024. PubMed
ONG WL, Loblaw A Radiotherapy for Unfavorable-risk Prostate Cancer: Biologic Dose Escalation,
Fewer Fractions, or Both?
Eur Urol. 2024 Oct 9:S0302-2838(24)02636-8. doi: 10.1016/j.eururo.2024. PubMed
ROUVIERE O, van Leenders GJLH, Eberli D Systematic Prostate Biopsy Versus Perilesional Sampling: If It Isn't Broke, Why
Fix It?
Eur Urol. 2024;86:295-296. PubMedAbstract available
BROWN JR, Sonpavde GP, Calaway A, Barata PC, et al Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How
Valuable?
Eur Urol. 2024;86:312-314. PubMed
CIMADAMORE A, Giannarini G, Crestani A, Lopez-Beltran A, et al How To Report the Minor Component of a High-grade Pattern in Radical
Prostatectomy Specimens: Time To Abandon the "Tertiary" Terminology?
Eur Urol. 2024;86:291-294. PubMedAbstract available
September 2024
GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III
Noninferiority Study Comparing Two Fractionation Schedules in Patients with
Low-Risk Prostate Cancer.
Eur Urol. 2024 Sep 26:S0302-2838(24)02613-7. doi: 10.1016/j.eururo.2024. PubMed
CARLSSON SV, Lilja H, Vickers AJ, Bjartell AS, et al Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk.
Eur Urol. 2024 Sep 25:S0302-2838(24)02615-0. doi: 10.1016/j.eururo.2024. PubMed
QI F Re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of
Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational
Burden as Biomarkers in Predicting Response to Immunotherapy in
Castration-resistant Prostate Cancer
Eur Urol. 2024 Sep 25:S0302-2838(24)02612-5. doi: 10.1016/j.eururo.2024. PubMed
VAN DEN BERGH RCN, Schoots IG, Cornford PA Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They
Necessary in the Magnetic Resonance Imaging Era?
Eur Urol. 2024 Sep 25:S0302-2838(24)02607-1. doi: 10.1016/j.eururo.2024. PubMedAbstract available
DAI YH, Chen PH, Lee DJ, Andrade G, et al A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of
Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy
Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer.
Eur Urol. 2024 Sep 25:S0302-2838(24)02608-3. doi: 10.1016/j.eururo.2024. PubMedAbstract available
RATHKOPF DE, Roubaud G, Chi KN, Efstathiou E, et al Patient-reported Outcomes for Patients with Metastatic Castration-resistant
Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized
Phase 3 MAGNITUDE Trial.
Eur Urol. 2024 Sep 23:S0302-2838(24)02594-6. doi: 10.1016/j.eururo.2024. PubMedAbstract available
UNTERRAINER M, Unterrainer LM, Ilhan H Re: Robert Seifert, Louise Emmett, Steven P. Rowe, et al. Second Version of the
Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including
Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023;83:405-12.
Eur Urol. 2024 Sep 23:S0302-2838(24)02617-4. doi: 10.1016/j.eururo.2024. PubMed
KLUMPER N, Eckstein M Reply to Feng Qi's Letter to the Editor re: Niklas Klumper, Viktor Grunwald,
Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair
Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to
Immunotherapy
Eur Urol. 2024 Sep 23:S0302-2838(24)02616-2. doi: 10.1016/j.eururo.2024. PubMed
CHEN DC, Thomson A, Mazzone E, Perera ML, et al Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for
Prostate Cancer.
Eur Urol. 2024 Sep 20:S0302-2838(24)02513-2. doi: 10.1016/j.eururo.2024. PubMed
FRANCINI E, Agarwal N, Castro E, Cheng HH, et al Intensification Approaches and Treatment Sequencing in Metastatic
Castration-resistant Prostate Cancer: A Systematic Review.
Eur Urol. 2024 Sep 20:S0302-2838(24)02599-5. doi: 10.1016/j.eururo.2024. PubMedAbstract available
BOEVE LMS, Hulshof MCCM, Verhagen PCMS, Twisk JWR, et al Prostate Cancer-related Events in Patients with Synchronous Metastatic
Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with
and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD
Trial.
Eur Urol. 2024 Sep 19:S0302-2838(24)02593-4. doi: 10.1016/j.eururo.2024. PubMedAbstract available
AZIZ MK, Molony D, Monlezun D, Holder T, et al Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States:
A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment
Histories.
Eur Urol. 2024 Sep 18:S0302-2838(24)02569-7. doi: 10.1016/j.eururo.2024. PubMedAbstract available
WEINER AB, Agrawal R, Wang NK, Sonni I, et al Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naive
Prostate Cancer.
Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024. PubMedAbstract available
BJERNER J, Bratt O, Aas K, Albertsen PC, et al Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor
re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific
Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from
the No
Eur Urol. 2024 Sep 17:S0302-2838(24)02575-2. doi: 10.1016/j.eururo.2024. PubMed
BRATT O Prostate Cancer Screening: Setting the Controls on the Mixing Board.
Eur Urol. 2024 Sep 17:S0302-2838(24)02598-3. doi: 10.1016/j.eururo.2024. PubMed
NIAZI T, Nabid A, Malagon T, Tisseverasinghe S, et al Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The
Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie
Genito-urinaire du Quebec-led Phase 3 Trial.
Eur Urol. 2024 Sep 12:S0302-2838(24)02574-0. doi: 10.1016/j.eururo.2024. PubMedAbstract available
VAN AS N, Yasar B, Griffin C, Patel J, et al Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised
Prostate Cancer: Results of the PACE-A Randomised Trial.
Eur Urol. 2024 Sep 11:S0302-2838(24)02568-5. doi: 10.1016/j.eururo.2024. PubMedAbstract available
LI R, Peng L, Zhang S, Wu S, et al Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific
Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from
the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20-6.
Eur Urol. 2024 Sep 5:S0302-2838(24)02564-8. doi: 10.1016/j.eururo.2024. PubMed
ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes
in Patients with Metastatic Castration-resistant Prostate Cancer Receiving
[(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.
Eur Urol. 2024 Sep 5:S0302-2838(24)02560-0. doi: 10.1016/j.eururo.2024. PubMedAbstract available
NAIR SS, Muhammad H, Jain P, Xie C, et al A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of
Prostate Cancer Progression in Patients with Clinical Intermediate Risk.
Eur Urol. 2024 Sep 3:S0302-2838(24)02496-5. doi: 10.1016/j.eururo.2024. PubMed
KASIVISVANATHAN V, Wai-Shun Chan V, Clement KD, Levis B, et al VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing
Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound
Guided Biopsy in the Detection of Prostate Cancer.
Eur Urol. 2024 Sep 3:S0302-2838(24)02559-4. doi: 10.1016/j.eururo.2024. PubMedAbstract available
VYNCKIER P, Annemans L, Roobol M Reply to Andres Gutierrez, Julio Cesar Boada, and Sebastian Pena's Letter to the
Editor re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review
on the Cost-effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In
press. ht
Eur Urol. 2024 Sep 2:S0302-2838(24)02566-1. doi: 10.1016/j.eururo.2024. PubMed
ACHARD V, Tombal B All Biochemical Recurrences Are Equal, but Some Are More Equal than Others.
Eur Urol. 2024;86:211-212. PubMed
August 2024
GUTIERREZ A, Boada JC, Pena S Re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the
Cost Effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press.
https://doi.org/10.1016/j.eururo.2024.04.036.
Eur Urol. 2024 Aug 30:S0302-2838(24)02565-X. doi: 10.1016/j.eururo.2024. PubMed
LEENEN RCA, Venderbos LDF, Helleman J, Gomez Rivas J, et al Prostate Cancer Early Detection in the European Union and UK.
Eur Urol. 2024 Aug 24:S0302-2838(24)02502-8. doi: 10.1016/j.eururo.2024. PubMedAbstract available
QI F Re: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, et al. Impact of
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed
Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a
Prospective Multicenter R
Eur Urol. 2024 Aug 21:S0302-2838(24)02557-0. doi: 10.1016/j.eururo.2024. PubMed
MAY M, Albersen M, Brookman-May S Re: Influential Factors Impacting Treatment Decision-making and Decision Regret
in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic
Literature Review.
Eur Urol. 2024 Aug 19:S0302-2838(24)02552-1. doi: 10.1016/j.eururo.2024. PubMed
BRATT O Re: Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml:
Results from the Goteborg-2 Prostate Cancer Screening Trial.
Eur Urol. 2024 Aug 17:S0302-2838(24)02523-5. doi: 10.1016/j.eururo.2024. PubMed
CHEN DC, Park H, McVey A, Lawrentschuk N, et al Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI
(PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
Eur Urol. 2024 Aug 17:S0302-2838(24)02520-X. doi: 10.1016/j.eururo.2024. PubMed
GORADIA R, Abdollah F, Sood A Re: Integrative Multi-Region Molecular Profiling of Primary Prostate Cancer in
Men with Synchronous Lymph Node Metastasis.
Eur Urol. 2024 Aug 6:S0302-2838(24)02497-7. doi: 10.1016/j.eururo.2024. PubMed
KAMRAN SC, Efstathiou JA Honing Stratification and Treatment for High-risk Prostate Cancer.
Eur Urol. 2024 Aug 6:S0302-2838(24)02489-8. doi: 10.1016/j.eururo.2024. PubMed
DI LORENZO G, Buonerba C Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with
Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Eur Urol. 2024 Aug 1:S0302-2838(24)02500-4. doi: 10.1016/j.eururo.2024. PubMed
THOMPSON IM JR Prostate-specific Antigen Screening in Limbo: How Low Should We Go?
Eur Urol. 2024;86:101-102. PubMed
MARRA G, Oderda M, Gontero P Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic
Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious
Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
Eur Urol. 2024;86:e36-e37. PubMed
July 2024
MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al Re: Long-term Prostate Cancer-specific Mortality After Prostatectomy,
Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring
for Localized Prostate Cancer.
Eur Urol. 2024 Jul 31:S0302-2838(24)02492-8. doi: 10.1016/j.eururo.2024. PubMed
PARK H, Chen DC, Mazzone E, Grummet J, et al Re: Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening. The
STHLM3-MRI Randomized Clinical Trial.
Eur Urol. 2024 Jul 19:S0302-2838(24)02452-7. doi: 10.1016/j.eururo.2024. PubMed
MAZZONE E, Perera S, Neti AL, Chen DC, et al Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic
Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre,
Randomised, Phase 2 Trial.
Eur Urol. 2024 Jul 19:S0302-2838(24)02450-3. doi: 10.1016/j.eururo.2024. PubMed
SPRATT DE, Liu VYT, Jia AY, Royce TJ, et al Meta-analysis of Individual Patient-level Data for a Multimodal Artificial
Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG
Phase 3 Randomized Trials.
Eur Urol. 2024 Jul 17:S0302-2838(24)02454-0. doi: 10.1016/j.eururo.2024. PubMed
HU JC, Schaeffer EM, Vickers AJ Reply to Ilias Giannakodimos' Letter to the Editor re: Jim C. Hu, Melissa Assel,
Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance
Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious
Complications: The PREV
Eur Urol. 2024;86:e13. PubMed
ROSEN GH, Chakiryan NH, Murray KS Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus
Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to
Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol.
2024;86:61-68.
Eur Urol. 2024;86:e14. PubMed
GIANNAKODIMOS I Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus
Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to
Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol.
2024;86:61-68.
Eur Urol. 2024;86:e12. PubMed
CHIU PK, Wu X, Gandaglia G Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus
Transrectal Prostate Biopsies.
Eur Urol. 2024;86:e16-e17. PubMed
HU JC, Assel M, Allaf ME, Ehdaie B, et al Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and
Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT
Randomized Trial.
Eur Urol. 2024;86:61-68. PubMedAbstract available
June 2024
TANEJA SS Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic
Resonance Imaging-targeted Biopsy on Prostate Cancer Mortality?
Eur Urol. 2024 Jun 19:S0302-2838(24)02413-8. doi: 10.1016/j.eururo.2024. PubMed
COOPERBERG MR PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic
Resonance Imaging in Prostate Cancer Active Surveillance.
Eur Urol. 2024 Jun 18:S0302-2838(24)02400-X. doi: 10.1016/j.eururo.2024. PubMed
SRIVASTAVA A, Lewicki P, Morgan TM Biomarkers in Prostate Cancer Screening: Sometimes "More is More".
Eur Urol. 2024 Jun 18:S0302-2838(24)02428-X. doi: 10.1016/j.eururo.2024. PubMed
RAYCHAUDHURI R, DeJong M, Rettig M, Yu EY, et al Docetaxel and Carboplatin for the Treatment of Patients with Metastatic
Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the
Homologous Recombination DNA Repair Pathway: The ABCD Trial.
Eur Urol. 2024 Jun 17:S0302-2838(24)02407-2. doi: 10.1016/j.eururo.2024. PubMed
MACEK P, Rodriguez-Sanchez L, Cathelineau X Re: Identification of the Optimal Candidates for Nodal Staging with Extended
Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent
Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography.
External Validation of
Eur Urol. 2024 Jun 13:S0302-2838(24)02401-1. doi: 10.1016/j.eururo.2024. PubMed
ADELEKE S High-performing, Accessible, and Affordable Imaging in Metastatic Prostate
Cancer: Is Whole-body Magnetic Resonance Imaging the Answer?
Eur Urol. 2024 Jun 12:S0302-2838(24)02410-2. doi: 10.1016/j.eururo.2024. PubMed
May 2024
VICKERS AJ Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading
on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate
Cancer Lead to Overtreatment? Eur Urol. In press.
https://doi.org/10.1016/j.eururo.2024.02.0
Eur Urol. 2024 May 25:S0302-2838(24)02385-6. doi: 10.1016/j.eururo.2024. PubMed
ULERI A, Baboudjian M, Diamand R, Ploussard G, et al Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Roder's Letter to the
Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does
Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in
Prostate Cancer L
Eur Urol. 2024 May 24:S0302-2838(24)02387-X. doi: 10.1016/j.eururo.2024. PubMed
ULERI A, Baboudjian M, Diamand R, Ploussard G, et al Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain
Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic
Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur
Urol. In
Eur Urol. 2024 May 24:S0302-2838(24)02386-8. doi: 10.1016/j.eururo.2024. PubMed
VYNCKIER P, Annemans L, Raes S, Amrouch C, et al Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in
Europe.
Eur Urol. 2024 May 23:S0302-2838(24)02378-9. doi: 10.1016/j.eururo.2024. PubMedAbstract available
WEINER AB, Kakani P, Armstrong AJ, Bossi A, et al Risk Stratification of Patients with Recurrence After Primary Treatment for
Prostate Cancer: A Systematic Review.
Eur Urol. 2024 May 22:S0302-2838(24)02375-3. doi: 10.1016/j.eururo.2024. PubMedAbstract available
RAVI P, Xie W, Buyse M, Halabi S, et al Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A
Pooled Analysis of Randomized Trials.
Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024. PubMedAbstract available
DALLA VOLTA A, Valcamonico F, Zivi A, Procopio G, et al Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the
Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer
Receiving Enzalutamide.
Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024. PubMed
JOSEFSSON A, Mansson M, Kohestani K, Spyratou V, et al Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the
GOTEBORG-2 Prostate Cancer Screening Trial.
Eur Urol. 2024 May 20:S0302-2838(24)02379-0. doi: 10.1016/j.eururo.2024. PubMedAbstract available
BROOKMAN-MAY SD, Buyse M, Freedland SJ, Miladinovic B, et al Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints
Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in
Nonmetastatic Prostate Cancer.
Eur Urol. 2024 May 17:S0302-2838(24)02348-0. doi: 10.1016/j.eururo.2024. PubMedAbstract available
PADHANI AR, Lecouvet F, Petralia G, Koh DM, et al Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body
Magnetic Resonance Imaging as a Treatment Response Biomarker in
Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical
Trial. Eur Urol. In press. http
Eur Urol. 2024 May 16:S0302-2838(24)02377-7. doi: 10.1016/j.eururo.2024. PubMed
GARCIA-RUIZ A, Macarro C, Mateo J, Perez-Lopez R, et al Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's
Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et
al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in
Castrati
Eur Urol. 2024 May 16:S0302-2838(24)02376-5. doi: 10.1016/j.eururo.2024. PubMed
FANKHAUSER CD, Wettstein MS, Wurnschimmel C, van Smeden M, et al Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and
Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish
Population-based Screening Cohort.
Eur Urol. 2024 May 15:S0302-2838(24)02340-6. doi: 10.1016/j.eururo.2024. PubMed
KRILAVICIUTE A, Kaaks R, Seibold P, de Vrieze M, et al Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data
from the PROBASE Trial.
Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024. PubMedAbstract available
STROOMBERG HV, Brasso K, Roder A Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading
on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate
Cancer Lead to Overtreatment? Eur Urol. In press.
https://doi.org/10.1016/j.eururo.2024.02.0
Eur Urol. 2024 May 14:S0302-2838(24)02365-0. doi: 10.1016/j.eururo.2024. PubMed
MERSEBURGER AS, Chowdhury S, Bahl A Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate
Cancer: Insights from the ARASENS Study.
Eur Urol. 2024 May 14:S0302-2838(24)02364-9. doi: 10.1016/j.eururo.2024. PubMed
CHIN JL Re: Incidence and Survival of Secondary Malignancies after External Beam
Radiotherapy for Prostate Cancer in the SEER Database.
Eur Urol. 2024 May 13:S0302-2838(24)02344-3. doi: 10.1016/j.eururo.2024. PubMed
KLUMPER N, Grunwald V, Hartmann A, Holzel M, et al The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor
Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in
Castration-resistant Prostate Cancer.
Eur Urol. 2024 May 13:S0302-2838(24)02350-9. doi: 10.1016/j.eururo.2024. PubMedAbstract available
OKOLI S, Okoli O, Ding H, Adeleke S, et al Re: Actinium-225-PSMA Radioligand Therapy of Metastatic Castration-resistant
Prostate Cancer (WARMTH Act): A Multicentre, Retrospective Study.
Eur Urol. 2024 May 11:S0302-2838(24)02352-2. doi: 10.1016/j.eururo.2024. PubMed
LIGHT A, Mayor N, Cullen E, Kirkham A, et al The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic
Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and
International Consensus Recommendations.
Eur Urol. 2024;85:466-482. PubMedAbstract available
ANAND M, Jain B, Aggarwal S Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al.
Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur
Urol 2023;84:491-502.
Eur Urol. 2024;85:e145. PubMed
HARTRAMPF PE, Rowe SP, Pomper MG, Higuchi T, et al Reply to Madhur Anand, Bela Jain, and Swati Aggarwal's Letter to the Editor re:
Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al.
Prostate-Specific Membrane Antigen Reporting and Data System Version 2.0. Eur
Urol 2023;84:491-502.
Eur Urol. 2024;85:e146-e147. PubMed
April 2024
TILKI D, van den Bergh RCN, Briers E, Van den Broeck T, et al EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update:
Treatment of Relapsing and Metastatic Prostate Cancer.
Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024. PubMedAbstract available
OST P, Siva S, Zilli T OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate
Cancer: Are We Already Full?
Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024. PubMed
HU JC, Vickers AJ, Schaeffer EM Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association
of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond
Statistical Significance: Unveiling the Advantages of Transperineal Versus
Transrectal Prostate
Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024. PubMed
SAAD F, Hussain MHA, Tombal B, Fizazi K, et al Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen
Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for
Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer:
Analyses of
Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024. PubMedAbstract available
HINDIE E, Champion C, Morgat C Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering
[(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk
Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2
Study. Eur Urol. In press.
Eur Urol. 2024 Apr 20:S0302-2838(24)02310-8. doi: 10.1016/j.eururo.2024. PubMed
CARDONA ORTEGON JD, Campana Perilla LA, Olarte Bermudez LM Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al.
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the
Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur
Urol 2024;85:105-11
Eur Urol. 2024 Apr 20:S0302-2838(24)02315-7. doi: 10.1016/j.eururo.2024. PubMed
CORNFORD P, van den Bergh RCN, Briers E, Van den Broeck T, et al EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I:
Screening, Diagnosis, and Local Treatment with Curative Intent.
Eur Urol. 2024 Apr 12:S0302-2838(24)02254-1. doi: 10.1016/j.eururo.2024. PubMedAbstract available
GRABBERT M, Liakos N, Gratzke C Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
Eur Urol. 2024 Apr 11:S0302-2838(24)02258-9. doi: 10.1016/j.eururo.2024. PubMed
RUSH HL, Gilbert DC, Langley RE Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix
Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer:
Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
Eur Urol. 2024 Apr 6:S0302-2838(24)02251-6. doi: 10.1016/j.eururo.2024. PubMed
ROY S, Fervaha G, Spratt DE, Sun Y, et al Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer:
A Network Meta-analysis.
Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024. PubMedAbstract available
ROY S, Saad F, Malone S, Agarwal N, et al Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in
Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN
Study.
Eur Urol. 2024;85:398-400. PubMed
O'CALLAGHAN M, Bulamu N, Gormly K, Jay A, et al Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a
Prostate Health Check: A Prospective Cohort Study.
Eur Urol. 2024;85:395. PubMed
March 2024
ENGLMAN C, Maffei D, Allen C, Kirkham A, et al PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic
Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024. PubMedAbstract available
LOGOTHETIS CJ, Hahn AW Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to
the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the
Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap
Syndrome. Eur Urol 2024
Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024. PubMed
WASSERSUG RJ, Schellhammer PF, Wibowo E Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing
Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol
2024;85:3-7.
Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024. PubMed
WINDISCH O, Valerio M Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of
Localised Clinically Significant Prostate Cancer in Patients >70 Years: A
Multi-institute, Multi-energy 15-year Experience.
Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024. PubMed
DE MEERLEER G, Joniau S, Benijts J, Rans K, et al Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024. PubMed
BURGER M Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted
Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of
Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing
Robotic-assisted Pro
Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024. PubMed
NIKITAS J, Rettig M, Shen J, Reiter R, et al Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer
(SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024. PubMedAbstract available
BABOUDJIAN M, Diamand R, Uleri A, Beauval JB, et al Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions
in Prostate Cancer Lead to Overtreatment?
Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024. PubMedAbstract available
CUSSENOT O, Chambaz A, Hamdy FC Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term
Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External
Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate
Cancer. Eur
Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024. PubMed
GARCIA-RUIZ A, Macarro C, Zacchi F, Morales-Barrera R, et al Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in
Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical
Trial.
Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024. PubMed
MOLLER F, Mansson M, Wallstrom J, Hellstrom M, et al Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml:
Results from the Goteborg-2 Prostate Cancer Screening Trial.
Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024. PubMedAbstract available
WEBER M, Fendler WP, Ravi Kumar AS, Calais J, et al Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease
Extent and Overall Survival of Patients with High-risk Nonmetastatic
Castration-resistant Prostate Cancer: An International Multicenter Retrospective
Study.
Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024. PubMedAbstract available
VAUGIER L, Morvan C, Pasquier D, Buthaud X, et al Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage
Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate
Cancer: OLIGOPELVIS (GETUG-P07).
Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024. PubMedAbstract available
NICKOLS NG, Tsai S, Kane N, Tran S, et al Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The
SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024. PubMed
MONTIRONI R, Cimadamore A, Giannarini G, Crestani A, et al Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish
Population.
Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024. PubMed
FODOR A, Brombin C, Chiti A, Di Muzio N, et al Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and
Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A
Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press.
https://doi.org/1
Eur Urol. 2024 Mar 12:S0302-2838(24)02140-7. doi: 10.1016/j.eururo.2024. PubMed
SARTOR O Prostate-specific Membrane Antigen-targeted Isotope Therapy: Inherent Challenges
Owing to Heterogeneity and Clonal Evolution.
Eur Urol. 2024;85:205-206. PubMed
PILATZ A, MacLennan S, van den Bergh RCN, Veeratterapillay R, et al Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus
Scientific Evidence and Equipoise. Eur Urol. 2024;85:99-100.
Eur Urol. 2024;85:313-314. PubMed
February 2024
GOLIJANIN B, Mega A, Golijanin D Re: Ivo I. de Vos II, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol,
ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After
Discontinuing Organised Screening: Long-term Results from the European Randomized
Study of Scr
Eur Urol. 2024 Feb 29:S0302-2838(24)00081-2. doi: 10.1016/j.eururo.2024. PubMed
POPE B, Park G, Lau E, Belic J, et al Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a
Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
Eur Urol. 2024 Feb 19:S0302-2838(24)00003-4. doi: 10.1016/j.eururo.2024. PubMed
FENG D, Wang J, Wu R, Li D, et al Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen
Deprivation Therapy Against Prostate Cancer.
Eur Urol. 2024 Feb 17:S0302-2838(24)00069-1. doi: 10.1016/j.eururo.2024. PubMed
DE VOS II, Remmers S, Roobol MJ Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the
Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol,
ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After
Discontinui
Eur Urol. 2024 Feb 17:S0302-2838(24)00057-5. doi: 10.1016/j.eururo.2024. PubMed
DEIVASIGAMANI S, Kotamarti S, Gupta RT, Polascik TJ, et al Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI:
Is It Time To Reconsider Scoring Categorization?
Eur Urol. 2024;85:180-181. PubMed
PREISSER F, Abrams-Pompe RS, Stelwagen PJ, Bohmer D, et al European Association of Urology Biochemical Recurrence Risk Classification as a
Decision Tool for Salvage Radiotherapy-A Multicenter Study.
Eur Urol. 2024;85:164-170. PubMedAbstract available
MIAN BM Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and
Equipoise.
Eur Urol. 2024;85:99-100. PubMedAbstract available
January 2024
ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al Impact of Prostate-specific Membrane Antigen Positron Emission
Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy
Management: Results from a Prospective Multicenter Randomized Phase 3 Trial
(PSMA-SRT NCT03582774).
Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024. PubMedAbstract available
VICKERS AJ, Assel M, Cooperberg MR, Fine SW, et al Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate
Cancer.
Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024. PubMedAbstract available
CHI KN, Armstrong AJ, Krause BJ, Herrmann K, et al Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients
with Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2024 Jan 6:S0302-2838(23)03297-9. doi: 10.1016/j.eururo.2023. PubMedAbstract available
December 2023
LIU M, Chen P, Li T Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone
Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate
Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised,
Double-blind, Phas
Eur Urol. 2023 Dec 21:S0302-2838(23)03293-1. doi: 10.1016/j.eururo.2023. PubMed
HUANG TB, Ding XF Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al.
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the
Age of 45 Years: Results from the First Screening Round of the PROBASE Trial, Eur
Urol. In press. htt
Eur Urol. 2023 Dec 16:S0302-2838(23)03294-3. doi: 10.1016/j.eururo.2023. PubMed
ALBERS P, van Poppel H Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer
Testing Program.
Eur Urol. 2023 Dec 15:S0302-2838(23)03290-6. doi: 10.1016/j.eururo.2023. PubMed
CORPETTI M, Muller C, Beltran H, de Bono J, et al Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer:
Towards Improving Therapeutic Outcomes.
Eur Urol. 2023 Dec 15:S0302-2838(23)03278-5. doi: 10.1016/j.eururo.2023. PubMedAbstract available
FERNANDEZ-ZAPATA WF, Gandur Quiroga MN, Cardona Maya WD Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate
Cancer.
Eur Urol. 2023 Dec 11:S0302-2838(23)03283-9. doi: 10.1016/j.eururo.2023. PubMed
RAGGI D, Cigliola A, Mercinelli C, Patane D, et al Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from
Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data
from Randomised Trials.
Eur Urol. 2023 Dec 11:S0302-2838(23)03260-8. doi: 10.1016/j.eururo.2023. PubMed
KAPLAN-MARANS E, Zhang TR, Hu JC Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budaus's Letter to
the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing
Recommendations on Prostate Biopsy Approach to Minimize Infections: An
Examination of the European A
Eur Urol. 2023;84:e151. PubMed
CAPOGROSSO P, Deho F, Salonia A, Briganti A, et al Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive
Treatments for Benign Prostatic Obstruction: A Systematic Review and Network
Meta-analysis. Eur Urol 2023;83:534-47.
Eur Urol. 2023;84:e146. PubMed
DJAILEB L, Armstrong WR, Thompson D, Gafita A, et al Presurgical (68)Ga-PSMA-11 Positron Emission Tomography for Biochemical
Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective
Phase 3 Imaging Trial.
Eur Urol. 2023;84:588-596. PubMedAbstract available
SAAD F, Del Rosario P, Clarke NW Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad,
Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo
plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel):
Final Prespe
Eur Urol. 2023 Dec 1:S0302-2838(23)03274-8. doi: 10.1016/j.eururo.2023. PubMed
BRATT O, Godtman RA, Jiborn T, Wallstrom J, et al Population-based Organised Prostate Cancer Testing: Results from the First
Invitation of 50-year-old Men.
Eur Urol. 2023 Dec 1:S0302-2838(23)03272-4. doi: 10.1016/j.eururo.2023. PubMedAbstract available
FALKENBACH F, Sanguedolce F, Budaus L Re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on
Prostate Biopsy Approach to Minimize Infections: An Examination of the European
Association of Urology and American Urological Association Guidelines. Eur Urol.
2023;84:44
Eur Urol. 2023;84:e149-e150. PubMed
November 2023
GIESEN A, Devlies W, Claessens F, Joniau S, et al Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2023 Nov 27:S0302-2838(23)03273-6. doi: 10.1016/j.eururo.2023. PubMed
DING L, Yang B, Yao X Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone
Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate
Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised,
Double-blind, Phas
Eur Urol. 2023 Nov 23:S0302-2838(23)03226-8. doi: 10.1016/j.eururo.2023. PubMed
MUN CHOW K, Zheng So W, Jie Lee H, Lee A, et al Corrigendum to "Head-to-head Comparison of the Diagnostic Accuracy of
Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional
Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate
Cancer: A Systematic R
Eur Urol. 2023 Nov 14:S0302-2838(23)03213-X. doi: 10.1016/j.eururo.2023. PubMed
MOORE CM, Albertsen P When Is It Too Early To Start Prostate Cancer Screening? Reflections on the
PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated
Prostate-specific Antigen.
Eur Urol. 2023 Nov 13:S0302-2838(23)03212-8. doi: 10.1016/j.eururo.2023. PubMed
HAMDY FC, Donovan JL Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor
re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year
Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J
Med 2023;388:
Eur Urol. 2023 Nov 8:S0302-2838(23)03218-9. doi: 10.1016/j.eururo.2023. PubMed
MISZCZYK M, Rajwa P, Yanagisawa T, Nowicka Z, et al The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate
Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
Eur Urol. 2023 Nov 7:S0302-2838(23)03209-8. doi: 10.1016/j.eururo.2023. PubMedAbstract available
TRUJILLO CG, Pena Rodriguez S, Diaz Ritter C Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive
Treatments for Benign Prostatic Obstruction: A Systematic Review and Network
Meta-analysis. Eur Urol. 2023;83:534-47.
Eur Urol. 2023;84:e116. PubMed
FENG T, Ren M, Zhou Z Re: Peter Fletcher, Marta De Santis, Simona Ippoliti, et al. Vector Prostate
Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal
Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia.
Eur Urol 2023
Eur Urol. 2023;84:e114. PubMed
LINDER S, Severson TM, van der Mijn KJC, Nevedomskaya E, et al Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven
Programs.
Eur Urol. 2023;84:455-460. PubMedAbstract available
WERNER RA, Hartrampf PE, Fendler WP, Serfling SE, et al Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
Eur Urol. 2023;84:491-502. PubMedAbstract available
October 2023
DE VOS II, Remmers S, Hogenhout R, Roobol MJ, et al Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised
Screening: Long-term Results from the European Randomized Study of Screening for
Prostate Cancer Rotterdam.
Eur Urol. 2023 Oct 31:S0302-2838(23)03207-4. doi: 10.1016/j.eururo.2023. PubMedAbstract available
SHAW G, Kelly JD, Roobol MJ Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year
Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J
Med 2023;388:1547-58.
Eur Urol. 2023 Oct 26:S0302-2838(23)03170-6. doi: 10.1016/j.eururo.2023. PubMed
EAPEN RS, Buteau JP, Jackson P, Mitchell C, et al Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with
High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm,
Phase 1/2 Study.
Eur Urol. 2023 Oct 25:S0302-2838(23)03087-7. doi: 10.1016/j.eururo.2023. PubMedAbstract available
SHARMA AD, Good DW, Alan McNeill S Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
Eur Urol. 2023 Oct 19:S0302-2838(23)03157-3. doi: 10.1016/j.eururo.2023. PubMed
BOSCHHEIDGEN M, Albers P, Schlemmer HP, Hellms S, et al Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the
Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Eur Urol. 2023 Oct 18:S0302-2838(23)03158-5. doi: 10.1016/j.eururo.2023. PubMedAbstract available
HERLEMANN A, Cowan JE, Washington SL 3rd, Wong AC, et al Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy,
External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized
Prostate Cancer.
Eur Urol. 2023 Oct 17:S0302-2838(23)03155-X. doi: 10.1016/j.eururo.2023. PubMedAbstract available
SORCE G, Mottrie A Re: Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed
in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study that Challenges
the Dogma.
Eur Urol. 2023 Oct 14:S0302-2838(23)03159-7. doi: 10.1016/j.eururo.2023. PubMed
GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating
Prostate-specific Membrane Antigen Positron Emission Tomography in Management
Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate
Cancer. Eur Urol 2
Eur Urol. 2023 Oct 11:S0302-2838(23)03140-8. doi: 10.1016/j.eururo.2023. PubMed
KRAFFT U, Hadaschik BA, Luckerath K, Herrmann K, et al A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
Eur Urol. 2023 Oct 11:S0302-2838(23)03149-4. doi: 10.1016/j.eururo.2023. PubMed
TOMBAL B, Collins S, Morgans AK, Hunsche E, et al Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced
Prostate Cancer: Results from the Phase 3 HERO Study.
Eur Urol. 2023 Oct 11:S0302-2838(23)03099-3. doi: 10.1016/j.eururo.2023. PubMedAbstract available
JUNG J, Kim JH Re: Casey Crump, Par Stattin, James D. Brooks, et al. Long-term Risks of
Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study.
Eur Urol 2023;84:263-72.
Eur Urol. 2023 Oct 11:S0302-2838(23)03154-8. doi: 10.1016/j.eururo.2023. PubMed
HICKS RJ The Pythia Speaks on Prostate Cancer Diagnosis and Treatment.
Eur Urol. 2023 Oct 11:S0302-2838(23)03148-2. doi: 10.1016/j.eururo.2023. PubMed
KISHAN AU, Valle LF, Marks LS Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in
Radiorecurrent Prostate Cancer.
Eur Urol. 2023 Oct 5:S0302-2838(23)03145-7. doi: 10.1016/j.eururo.2023. PubMed
COLE AP, Gupta N, Loeb S The Plant-based Prescription: How Dietary Change Can Improve Both Urological and
Planetary Health.
Eur Urol. 2023;84:357-358. PubMedAbstract available
HEIJNSDIJK EAM, de Koning HJ Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and
Personal Approach.
Eur Urol. 2023;84:359-360. PubMed
September 2023
LIGHT A, Kanthabalan A, Otieno M, Pavlou M, et al The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of
Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
Eur Urol. 2023 Sep 29:S0302-2838(23)03089-0. doi: 10.1016/j.eururo.2023. PubMedAbstract available
LAMBERT E, Roupret M Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant
Prostate Cancer.
Eur Urol. 2023 Sep 27:S0302-2838(23)03137-8. doi: 10.1016/j.eururo.2023. PubMed
BEATRICI E, Labban M, Stone BV, Filipas DK, et al Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the
USA from 2010 to 2020: Insights from the National Cancer Data Base.
Eur Urol. 2023 Sep 25:S0302-2838(23)03088-9. doi: 10.1016/j.eururo.2023. PubMedAbstract available
PONTES-SILVA A Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo
Prostate Cancer Patient Empowerment Program Decreases Psychological Distress
Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical
Trial. Eur Urol 2023
Eur Urol. 2023 Sep 25:S0302-2838(23)03094-4. doi: 10.1016/j.eururo.2023. PubMed
ILIE G, Rutledge RDH Reply to Andre Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo
Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient
Empowerment Program Decreases Psychological Distress Among Men Undergoing
Curative Prostate Cancer Tr
Eur Urol. 2023 Sep 22:S0302-2838(23)03091-9. doi: 10.1016/j.eururo.2023. PubMed
MAY M, Wolff I, Brookman-May SD Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo
Prostate Cancer Patient Empowerment Program Decreases Psychological Distress
Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical
Trial. Eur Urol 2023
Eur Urol. 2023 Sep 22:S0302-2838(23)03095-6. doi: 10.1016/j.eururo.2023. PubMed
KLOTZ L Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to
Oncologic Outcomes After Prostatectomy.
Eur Urol. 2023 Sep 22:S0302-2838(23)03080-4. doi: 10.1016/j.eururo.2023. PubMed
OPREA-LAGER DE, MacLennan S, Bjartell A, Briganti A, et al European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging
and Theranostics in Prostate Cancer.
Eur Urol. 2023 Sep 22:S0302-2838(23)03092-0. doi: 10.1016/j.eururo.2023. PubMedAbstract available
ILIE G, Rutledge RDH Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the
Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo
Prostate Cancer Patient Empowerment Program Decreases Psychological Distress
Among Men Un
Eur Urol. 2023 Sep 22:S0302-2838(23)03093-2. doi: 10.1016/j.eururo.2023. PubMed
VAN POPPEL H, Roobol MJ, Chandran A Early Detection of Prostate Cancer in the European Union: Combining Forces with
PRAISE-U.
Eur Urol. 2023 Sep 11:S0302-2838(23)03023-3. doi: 10.1016/j.eururo.2023. PubMedAbstract available
MICHEL MC Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening.
Eur Urol. 2023 Sep 9:S0302-2838(23)03081-6. doi: 10.1016/j.eururo.2023. PubMed
ROCCO B, Sighinolfi MC Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year
Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J
Med 2023; 388:1547-58.
Eur Urol. 2023 Sep 6:S0302-2838(23)03069-5. doi: 10.1016/j.eururo.2023. PubMed
August 2023
PAPACHRISTODOULOU A, Heidegger I, Virk RK, Di Bernardo M, et al Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer
Progression.
Eur Urol. 2023 Aug 31:S0302-2838(23)03016-6. doi: 10.1016/j.eururo.2023. PubMedAbstract available
HAMDY FC, Donovan JL Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re:
Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes
after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med
2023;388:1547-
Eur Urol. 2023 Aug 31:S0302-2838(23)03070-1. doi: 10.1016/j.eururo.2023. PubMed